Concepedia

Author

Parameswaran Hari

Medical College of WisconsinORCID

Also Known As

Bolwell, Brian J., Cairo, Mitchell S., Costa, Luciano J., Ganguly, Siddhartha, Gilbert C. White, Hari P S, Hari P. S., Hari, Parameswaran, Horowitz, Mary M, Jeanne Palmer

916

Publications

26.4K

Citations

79

H-Index

178

Concepts

All Affiliations

Medical College of WisconsinThe University of Texas MD Anderson Cancer CenterDana-Farber Cancer InstituteFred Hutch Cancer CenterMemorial Sloan Kettering Cancer Center
PH

About

Parameswaran Hari is an author at Medical College of Wisconsin specializing in medicine, immunology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

41

113

8.8K

2

Health Sciences

23

41

3.4K

3

Public Health

5

5

292

4

Education

1

1

10

5

Natural Sciences

1

1

13

Parameswaran Hari

×

294

Publications

20.8K

Citations

70

H-Index

YearCitations

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani,

The Lancet

2021

1.5K

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister,

New England Journal of Medicine

2012

1.1K

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros,

The Lancet Oncology

2019

772

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

Ujjawal H. Gandhi, Robert F. Cornell, Arjun Lakshman,

Leukemia

2019

597

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja,

Journal of Clinical Oncology

2022

580

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Shaji Kumar, Ian W. Flinn, Paul G. Richardson,

Blood

2012

449

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Nirav N. Shah, Bryon D. Johnson, Dina Schneider,

Nature Medicine

2020

439

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Shaji Kumar, Meletios Α. Dimopoulos, Efstathios Kastritis,

Leukemia

2017

348

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

Mohamed L. Sorror, Brenda M. Sandmaier, Barry E. Storer,

JAMA

2011

315

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

Amrita Krishnan, Marcelo C. Pasquini, Brent R. Logan,

The Lancet Oncology

2011

277

Page 1